Bio-Path Q1 net loss $3.2M ($4.88/sh); raises $3.5M post-quarter

BIO-PATH HOLDINGS, INC.

2024-Q1 EPS reported -$4.88

Net loss $3.2M ($4.88 EPS) vs $5.3M ($13.25 EPS) in Q1 2023; R&D expense down to $2.3M from $4.0M.
Cash at Mar 31 only $0.2M; raised $3.5M in April via $1.2M direct offering and $2.3M ATM sales.
Completed second dose cohort (40 mg/m2) of Phase 1/1b BP1002 trial for relapsed AML; pause for FDA review.
Patent portfolio expanded to 5 U.S. and 54 foreign patents covering 21 countries; new applications filed.
First dose cohort of Phase 1 BP1002 trial for relapsed lymphoma/CLL completed in January.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2024 results: net income $3.2 million, or $4.88 per share, EPS $4.88 per share.

Period: first quarter ended March 31, 2024
Net income: $3.2 million, or $4.88 per share
EPS: $4.88 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $3.2 million, or $4.88 per share, for the three months ended March 31, 2024, compared to a net loss of $5.3 million, or $13.25 per share, for the three months ended March 31, 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001544784-24-000068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.